EcoDrugPlus

Kit Proto-Oncogene, Receptor Tyrosine Kinase B

Ensembl ID : ENSACIG00000001202
Gene Symbol: KITB
1 Cross references
207 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSACIG00000003036
Gene Symbol: LYN
1 Cross references
196 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSACIG00000024180
Gene Symbol: MALT1
1 Cross references
198 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSACIG00000023055
Gene Symbol: MAPKAPK2
1 Cross references
186 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSACIG00000004891
Gene Symbol: MAPKAPK5
1 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSACIG00000012576
Gene Symbol: MKNK2B
1 Cross references
208 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSACIG00000004637
Gene Symbol: MCL1B
1 Cross references
212 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSACIG00000022117
Gene Symbol: MET
1 Cross references
204 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog (S. Cerevisiae)

Ensembl ID : ENSACIG00000003877
Gene Symbol: MLST8
1 Cross references
198 Possible Orthologues:

N-Acetylated Alpha-Linked Acidic Dipeptidase 2

Ensembl ID : ENSACIG00000009207
Gene Symbol: NAALAD2
1 Cross references
339 Possible Orthologues:

Nad(P)h Dehydrogenase, Quinone 1

Ensembl ID : ENSACIG00000019607
Gene Symbol: NQO1
2 Cross references
186 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSACIG00000020023
Gene Symbol: NPC1L1
2 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).